Abstract

Development of Small Molecule NUDT22 Inhibitors for Uses in Cancer [†]

Melanie Walter ¹ , Evert Homan ², Tobias Koolmeister ², Ingrid Almlöf ², Oliver Mortusewicz ², Thomas Helleday ^{1,2} and Patrick Herr ^{1,*}

¹ Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; mwalter3@sheffield.ac.uk (M.W.); t.helleday@sheffield.ac.uk (T.H.)

² Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Oncology and Pathology, Karolinska Institutet, SE-171 76 Stockholm, Sweden; evert.homan@ki.se (E.H.); tobias.koolmeister@ki.se (T.K.); ingrid.almlof@ki.se (I.A.); oliver.mortusewicz@ki.se (O.M.)

* Correspondence: p.herr@sheffield.ac.uk

[†] Presented at the 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, 1–14 February 2021; Available online: <https://iecc2021.sciforum.net/>.

Abstract: Here, we present the characterisation of the so-far-unstudied NUDIX hydrolase family member NUDT22. We previously identified the unique hydrolase activity of NUDT22 towards UDP-glucose from a family-wide biochemical substrate screen. UDP-glucose hydrolysis was found to result in the production of uridine monophosphate (UMP) and glucose 1-phosphate (G-1-P). We furthermore solved the first crystal structure of NUDT22 in complex with its substrate UDP-glucose [1]. Our mechanistic studies revealed increased replication stress in *NUDT22*-deficient cells that could be rescued by nucleoside supplementation. We therefore propose the discovery of a novel NUDT22-mediated pyrimidine salvage pathway. Increased replication rates resulting in replication stress is a hallmark of cancer cells, and *NUDT22* gene expression alterations are present in several cancer tissues, which makes NUDT22 an interesting new target for the development of small molecule inhibitors for uses in cancer. We employed our NUDT22 crystal structure to perform an *in silico* docking screen on available small molecule libraries to identify starting points for the development of first-in-class NUDT22 inhibitors. Chemically optimised NUDT22 inhibitors are currently being validated in biochemical assays and cellular target engagement assays, and their cellular activity is being assessed in vitro.

Keywords: NUDIX protein family; pyrimidine salvage pathway; DNA replication stress; first-in-class inhibitors

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/IECC2021-09197/s1>.

Reference

1. Carter, M.; Jemth, A.S.; Carreras-Puigvert, J.; Herr, P.; Carranza, M.M.; Vallin, K.S.; Throup, A.; Helleday, T.; Stenmark, P. Human NUDT22 Is a UDP-Glucose/Galactose Hydrolase Exhibiting a Unique Structural Fold. *Structure* **2018**, *26*, 295–303. [[CrossRef](#)] [[PubMed](#)]

Citation: Walter, M.; Homan, E.; Koolmeister, T.; Almlöf, I.; Mortusewicz, O.; Helleday, T.; Herr, P. Development of Small Molecule NUDT22 Inhibitors for Uses in Cancer. *Med. Sci. Forum* **2021**, *3*, 1. <https://doi.org/10.3390/IECC2021-09197>

Academic Editors: Nicola Curtin and Helen E. Bryant

Published: 29 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).